Recent Data on Anti-TROP2 ADCs for Patients With Advanced or Recurrent Endometrial Cancer

The panel highlights recent data on antibody drug conjugates targeting TROP2 in patients with advanced or recurrent endometrial cancer and the need for dose optimization.

Related Keywords

,Recent Advances ,Treating Endometrial ,Cervical Cancers ,Patients With Advanced ,Recurrent Endometrial ,Gynecologic Cancers ,Endometrial Cancer ,Endometrial Carcinoma ,Cervical Cancer ,